Molecular Basis for the Susceptibility of Fibrin-bound Thrombin to Inactivation by Heparin Cofactor II in the Presence of Dermatan Sulfate but Not Heparin

This publication has 44 references indexed in Scilit:

• Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention
  Chest, 2001
• Exosites 1 and 2 Are Essential for Protection of Fibrin-bound Thrombin from Heparin-catalyzed Inhibition by Antithrombin and Heparin Cofactor II
  Journal of Biological Chemistry, 1999
• Binding of Fibrin Monomer and Heparin to Thrombin in a Ternary Complex Alters the Environment of the Thrombin Catalytic Site, Reduces Affinity for Hirudin, and Inhibits Cleavage of Fibrinogen
  Published by Elsevier ,1996
• Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials
  BMJ, 1996
• Molecular mapping of the heparin-binding exosite of thrombin.
  Proceedings of the National Academy of Sciences, 1994
• ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction
  Published by Elsevier ,1992
• Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
  Journal of Clinical Investigation, 1990
• In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin
  The Lancet, 1990
• Structural and functional properties of human α-thrombin, phosphopyridoxylated α-thrombin, and γT-thrombin
  Published by Elsevier ,1989
• Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.
  Proceedings of the National Academy of Sciences, 1989